Project Details
| Short title | 1479-0001 |
|---|---|
| Status | Active |
| Effective start/end date | 13/08/23 → 14/06/28 |
CTU: 1479-0001 - An open label, Phase I dose escalation trial, with dose confirmation and expansion, of BI 1810631 as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations
- Park, John (Primary Chief Investigator)
- Chapman, Nicola (Clinical Trial Unit Staff)
- Contacos, Christine (Clinical Trial Unit Staff)
- Keshiya, Shikara (Clinical Trial Unit Staff)
Project: Research